Payment overview · 2025
General Payments
$4,559.71
102 reported records · 27 companies
Healthcare provider profile · identity verified
Roy T Avalos, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ENCINITAS, CA · NPI 1154399632
Verified facts
What the public records show
CMS Open Payments records show Roy T Avalos, M.D. received $4,559.71 in general payments during 2025 across 102 reported records.
AOP Health US, LLC accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 382 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 382 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $947.62 | 20.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $503.65 | 11.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $343.35 | 7.5% | 8 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $326.95 | 7.2% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $310.68 | 6.8% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $274.94 | 6.0% | 7 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $219.49 | 4.8% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $207.29 | 4.5% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $197.26 | 4.3% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$193.94 | 4.2% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $185.05 | 4.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.53 | 3.2% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $116.13 | 2.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $111.69 | 2.5% | 5 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $108.28 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.94 | 2.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.85 | 0.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.42 | 0.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.77 | 0.7% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $29.40 | 0.6% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $27.13 | 0.6% | 1 | 2025 |
| Getinge USA Sales, LLC | Unresolved — no canonical attribution shown | $24.83 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.11 | 0.5% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $22.74 | 0.5% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $20.70 | 0.5% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $13.49 | 0.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $5.48 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,559.71 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $947.62 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $326.95 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $308.28 | 6 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $274.94 | 7 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $246.21 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $246.21 | 4 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $219.49 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $197.26 | 10 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $185.05 | 5 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $153.53 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $116.13 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $113.36 | 6 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $108.28 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $94.94 | 4 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $75.57 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $75.49 | 4 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $68.37 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $64.47 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $49.20 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOSAVE RESCUE Normalized: cardiosave rescue |
Device | Getinge USA Sales, LLC | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $5.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 382 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
382 | 99 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
382 | 99 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 110 |
| Eliquis | Apixaban | 382 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 99 |
| Furosemide | Furosemide | 276 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 75 |
| Losartan Potassium | Losartan Potassium | 251 | 89 |
| Propafenone Hcl | Propafenone Hcl | 168 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 51 |
| Carvedilol | Carvedilol | 158 | 46 |
| Lisinopril | Lisinopril | 143 | 44 |
| Warfarin Sodium | Warfarin Sodium | 126 | 25 |
| Valsartan | Valsartan | 121 | 40 |
| Sotalol | Sotalol Hcl | 107 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 28 |
| Xarelto | Rivaroxaban | 72 | 22 |
| Repatha Sureclick | Evolocumab | 68 | 20 |
| Ezetimibe | Ezetimibe | 54 | 25 |
| Entresto | Sacubitril/Valsartan | 50 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 50 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 15 |
| Nitroglycerin | Nitroglycerin | 42 | 34 |
| Potassium Chloride | Potassium Chloride | 40 | 11 |
| Ranolazine Er | Ranolazine | 38 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 11 |
| Midodrine Hcl | Midodrine Hcl | 32 | 11 |
| Praluent Pen | Alirocumab | 32 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 12 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 11 |
| Carvedilol Er | Carvedilol Phosphate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,559.71 · 102 records | AOP Health US, LLC | AMPLATZER AMULET, AMVUTTRA, AREXVY, AURORA EV-ICD MRI SURESCAN, AVVIGO Guidance System, AZURE XT DR MRI SURESCAN, Assure WCD, Barostim Neo System, CAMZYOS, CAPVAXIVE, CARDIOSAVE RESCUE, CDS - MCT/CEM Monitoring, CT THROMBECTOMY SYSTEM KIT, Cleerly Ischemia, Cleerly Labs, ELIQUIS, EVKEEZA, FARXIGA, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, NEXLETOL, OPSUMIT, REPATHA, Rapiblyk, SHINGRIX, SYMPHONY CATHETER, UPTRAVI, VERQUVO, VYNDAQEL, WAINUA, WATCHMAN FLX, WaveWriter Alpha Prime 16 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error